Literature DB >> 1597159

Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption.

A S Alam1, A Gallagher, V Shankar, M A Ghatei, H K Datta, C L Huang, B S Moonga, T J Chambers, S R Bloom, M Zaidi.   

Abstract

The abundance of endothelin (ET)-producing endothelial cells in bone marrow and the proximity of these cells to bone-resorbing osteoclasts prompted us to evaluate the action of ET-1 on osteoclast function. Osteoclasts disaggregated from neonatal rat long bones were settled onto devitalized cortical bone substrate, and resorption was quantified by morphometry. The supernatant tartrate-resistant acid phosphatase activity was determined by a spectrophotometric method using paranitrophenol phosphate as substrate. Cell motility was quantified by time lapse video- and computer-assisted image processing using an empirical procedure for morphometric analysis. Cytosolic free calcium levels ([Ca2+]i) were measured in single cells by an indo 1-based microspectrofluorimetric method. Using the area of bone resorbed per slice as response, we found that ET-1 caused a significant (P = 0.011) concentration-dependent inhibition of osteoclastic bone resorption (EC50 = 2.5 nM) without inhibiting acid phosphatase secretion. Exposure of isolated osteoclasts to ET-1 also led to a marked concentration-dependent inhibition of osteoclast motility (EC50 = 7.9 nM; P = 0.013; t1/2 = 18 min) without significant effects on cell spread area. These effects of ET-1 were reversible after removing the peptide, and the cells remained viable during the experiments. In addition, ET-1 did not elevate [Ca2+]i at the concentrations tested. The results suggest that ET-1 specifically interacts with an osteoclast receptor to inhibit osteoclastic bone resorption and cell motility. As the concentration of ET-1 required for osteoclast inhibition was similar to that reported for smooth muscle contraction, it is possible that ET-1, produced locally from the bone marrow endothelial cell, might play a primary role in osteoclast regulation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1597159     DOI: 10.1210/endo.130.6.1597159

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  18 in total

Review 1.  Paget's disease of bone: diagnosis and treatment update.

Authors:  M Noor; D Shoback
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

2.  Comments on "cyclosporin does not affect the absolute rate of cortical bone resorption at the organ level in the growing rat".

Authors:  S Epstein; W S Jee; Y Ma; C C Liu
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

3.  Endothelin concentrations are elevated in plasma of patients with primary and secondary hyperparathyroidism.

Authors:  P Lakatos; A Tátrai; J Földes; C Horváth; J Makó; P H Stern
Journal:  Calcif Tissue Int       Date:  1996-01       Impact factor: 4.333

4.  Detection and characterization of endothelin in transformed human osteoblast cell culture medium.

Authors:  H C Lam; J K Lee; K H Lai
Journal:  Endocrine       Date:  2000-02       Impact factor: 3.633

Review 5.  Mechanical, hormonal and metabolic influences on blood vessels, blood flow and bone.

Authors:  Rhonda D Prisby
Journal:  J Endocrinol       Date:  2017-08-16       Impact factor: 4.286

6.  Lack of effect of ipriflavone on osteoclast motility and bone resorption in in vitro and ex vivo studies.

Authors:  K Notoya; S Taketomi; M Tsuda
Journal:  Calcif Tissue Int       Date:  1993-07       Impact factor: 4.333

7.  Endothelin receptor A blockade enhances taxane effects in prostate cancer.

Authors:  Ardavan Akhavan; Kevin H McHugh; Georgi Guruli; Robert R Bies; William C Zamboni; Sandra A Strychor; Joel B Nelson; Beth R Pflug
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

8.  A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.

Authors:  William R Schelman; Glenn Liu; George Wilding; Thomas Morris; De Phung; Robert Dreicer
Journal:  Invest New Drugs       Date:  2009-09-19       Impact factor: 3.850

Review 9.  Endothelin-1 as a target for therapeutic intervention in prostate cancer.

Authors:  E Scott Kopetz; Joel B Nelson; Michael A Carducci
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

10.  A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.

Authors:  Juan Juan Yin; Khalid S Mohammad; Sanna M Käkönen; Stephen Harris; J Ruth Wu-Wong; Jerry L Wessale; Robert J Padley; I Ross Garrett; John M Chirgwin; Theresa A Guise
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.